Elicio Therapeutics Shares Plunge 47% After Pancreatic Cancer Trial Failure
ELTX•Elicio Therapeutics shares fell 47% after its Phase 2 AMPLIFY-7P trial of ELI-002 7P in resected Stage I-III KRAS-driven pancreatic cancer missed its disease-free survival goal due to baseline imbalances. In 84% of participants with complete (R0) resections, median DFS was 23.8 vs 12.8 months (HR 0.65).
1. Trial Failure and Share Impact
Elicio Therapeutics saw its shares tumble 47% after the AMPLIFY-7P Phase 2 trial of ELI-002 7P in resected Stage I-III KRAS-driven pancreatic adenocarcinoma failed to achieve its primary disease-free survival endpoint in the intent-to-treat analysis.
2. Baseline Imbalance Influences Results
The company cited a key imbalance in resection status: 19% of patients in the ELI-002 arm had R1 resections versus 10% in the observation group, with R1 status linked to higher recurrence risk, potentially skewing intent-to-treat outcomes.
3. Post-Hoc Analysis Highlights R0 Benefit
In a retrospective review of fully resected (R0) patients, representing 84% of participants, ELI-002 7P delivered a median disease-free survival of 23.8 months versus 12.8 months for observation (HR 0.65, p=0.048), including a 14% absolute DFS advantage at three and six months.
4. Refined Phase 3 Strategy and Cash Position
Elicio plans to focus its Phase 3 program on R0 resected patients with enhanced dosing beyond the current vaccination schedule and booster regimen. The company expects its existing cash balance to fund operations into Q4 2026.
